Mind Medicine (MindMed) Inc
F:MMQ
Mind Medicine (MindMed) Inc
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company is headquartered in New York City, New York. The company went IPO on 2015-05-04. The firm is engaged in developing products to treat brain health disorders. The company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM-120 is a pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company is headquartered in New York City, New York. The company went IPO on 2015-05-04. The firm is engaged in developing products to treat brain health disorders. The company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM-120 is a pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Pivotal Trials Progress: MindMed remains on track with enrollment in three Phase III trials for MM120 ODT in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD), with top-line data expected in 2026.
Financial Position: The company ended Q2 2025 with $237.9 million in cash, cash equivalents, and investments, guiding operations funded into 2027 and at least 12 months beyond the first Phase III readout.
R&D Investment: Research and development expenses rose to $29.8 million, up from $14.6 million last year due to increased investment in MM120 ODT and higher headcount.
Commercial Readiness: Preparations for MM120 commercialization are underway, including market access strategies, targeting high-volume GAD treatment centers, and building messaging platforms.
Trial Design and Retention: Adaptive trial designs and open-label extension phases are intended to optimize statistical power and patient retention, with dropout rates expected to improve over prior studies.
Leadership Expansion: Brandi Roberts joined as CFO, bringing extensive industry experience to support financial strategy and growth.
Durability and Real-World Use: Management expects durable efficacy from MM120 and flexible, patient-specific dosing intervals in real-world settings, to be further clarified in upcoming studies.
